Company Description
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2005 |
| IPO Date | Mar 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 270 |
| CEO | Michael Metzger |
Contact Details
Address: 730 Third Avenue, 9th Floor New York, New York 10017 United States | |
| Phone | 781 419 1400 |
| Website | syndax.com |
Stock Details
| Ticker Symbol | SNDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001395937 |
| CUSIP Number | 87164F105 |
| ISIN Number | US87164F1057 |
| Employer ID | 32-0162505 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Metzger M.B.A. | Chief Executive Officer and Director |
| Dr. Neil Gallagher M.D., Ph.D. | President and Head of Research and Development |
| Keith Alan Goldan CPA | Chief Financial Officer, Treasurer and Chief Accounting Officer |
| Luke J. Albrecht J.D. | Senior Vice President, General Counsel and Secretary |
| Steven Closter | Chief Commercial Officer |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Sharon Klahre | Vice President of Investor Relations and Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 1, 2025 | ARS | Filing |
| Apr 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 7, 2025 | SCHEDULE 13G/A | Filing |
| Mar 4, 2025 | 144 | Filing |
| Mar 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |